| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
Alfa Chemistry |
| Tel: |
1-516-6625404 |
| Email: |
support@alfa-chemistry.com |
|
| | Naphthofluorescein Basic information |
| Product Name: | Naphthofluorescein | | Synonyms: | NAPHTHOFLUORESCEIN, FOR FLUORESCENCE;NAPHTHOFLUORESCEIN FOR FLUORESCENCE 95+%;Naphthafluorescein;Spiro[7H-dibenzo[c,h]xanthene-7,1'(3'H)-isobenzofuran]-3'-one,3,11-dihydroxy-;Naphthofluorescein | | CAS: | 61419-02-1 | | MF: | C28H16O5 | | MW: | 432.42 | | EINECS: | 634-716-5 | | Product Categories: | | | Mol File: | 61419-02-1.mol |  |
| | Naphthofluorescein Chemical Properties |
| Melting point | 189 °C (dec.)(lit.) | | Boiling point | 755.5±60.0 °C(Predicted) | | density | 1.58±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: soluble | | form | A crystalline solid | | pka | 8.82±0.20(Predicted) | | color | Purple to purplish red | | BRN | 61335 | | InChI | 1S/C28H16O5/c29-17-7-9-19-15(13-17)5-11-23-25(19)32-26-20-10-8-18(30)14-16(20)6-12-24(26)28(23)22-4-2-1-3-21(22)27(31)33-28/h1-14,29-30H | | InChIKey | IXQIUDNVFVTQLJ-UHFFFAOYSA-N | | SMILES | Oc1ccc2c3Oc4c(ccc5cc(O)ccc45)C6(OC(=O)c7ccccc67)c3ccc2c1 | | EPA Substance Registry System | Spiro[7H-dibenzo[c,h]xanthene-7,1'(3'H)-isobenzofuran]-3'-one, 3,11-dihydroxy- (61419-02-1) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 | | F | 8-10 | | TSCA | TSCA listed | | HS Code | 29329990 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | Naphthofluorescein Usage And Synthesis |
| Uses | Naphtofluorescein is a pH-sensitive fluorescent probe, also used for preparation of labels and enzyme substrates. | | Uses | Naphthofluorescein is a furin inhibitor. | | Definition | ChEBI: Naphthofluorescein is a member of xanthenes. | | in vivo | Naphthofluorescein (compound 19) (100 mg/kg; i.p.; once daily for 5 consecutive days followed by 2 days off for 2 weeks)does not show weight loss or apparent histological abnormalities in the lung, liver, and kidney, or cause cause severe adverse effects for at least 2 weeks in mice[1].
Naphthofluorescein (compound 19) (100 mg/kg; i.p.; once daily for 5 consecutive days followed by 2 days off for 2 weeks) strikingly suppresses the tumour growth of subcutaneously injected E0771 cells and significantly attenuates tumour growth of MDA-MB-231 and AsPC-1 cells in immunodeficient mice. In turn, naphthofluorescein does not attenuate tumour growth of FIH-1-depleted MDA-MB-231 cells[1].
Naphthofluorescein (compound 19) (100 mg/kg; i.p.; once daily for 5 consecutive days followed by 2 days off for 2 weeks) suppresses tumour growth in human cancer cells in an FIH-1-dependent manner[1]. | Animal Model: | Male C57BL/6J mice (8 weeks)[1] | | Dosage: | 100 mg/kg | | Administration: | i.p.; once daily for 5 consecutive days followed by 2 days off for 2 weeks | | Result: | Neither showed weight loss or apparent histological abnormalities in the lung, liver, and kidney, or caused cause severe adverse effects for at least 2 weeks in mice.
|
| Animal Model: | Female C57BL/6J mice (E0771) and BALB/c nude mice (HT1080, MDA-MB-231, and AsPC-1) (6 weeks)[1] | | Dosage: | 100 mg/kg | | Administration: | i.p.; once daily for 5 consecutive days followed by 2 days off for 2 weeks | | Result: | Strikingly suppressed the tumour growth of subcutaneously injected E0771 cells and significantly attenuated tumour growth of MDA-MB-231 and AsPC-1 cells in immunodeficient mice. In turn, naphthofluorescein did not attenuate tumour growth of FIH-1-depleted MDA-MB-231 cells.
|
|
| | Naphthofluorescein Preparation Products And Raw materials |
|